Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Next Previous
X
Search
Trial Profile

A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VBP 926 (Primary)
  • Indications Paronychia
  • Focus Therapeutic Use
  • Sponsors Veloce BioPharma

    • Most Recent Events

    • 26 Jun 2019 Results assessing efficacy and safety of a topical povidone-iodine formulation in patients with paronychia published in the Investigational New Drugs
    • 09 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2018 According to a Veloce BioPharma media release, Mario Lacouture, MD, Director, Oncodermatology Program at Memorial Sloan Kettering Cancer Center is one of the lead investigators of the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top